Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.727
Index Copernicus  – 166.39
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2015, vol. 24, nr 1, January-February, p. 63–68

doi: 10.17219/acem/34555

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Porphobilinogen Deaminase Gene Mutations in Polish Patients with Non-Erythroid Acute Intermittent Porphyria

Urszula Szlendak1,A,B,C,D, Agnieszka Lipniacka2,B,D, Jolanta Bianketti3,B, Maria Podolak-Dawidziak4,D,E, Ksenia Bykowska2,D,E,F

1 Department of Immunogenetics, Institute of Haematology and Transfusion Medicine, Warszawa, Poland

2 Department of Hemostasis and Metabolic Disorders, Institute of Haematology and Transfusion Medicine, Warszawa, Poland

3 Department of Hematology, Institute of Haematology and Transfusion Medicine, Warszawa, Poland

4 Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Wrocław, Poland

Abstract

Background. Acute intermittent porphyria (AIP) is an metabolic disorder characterized by a partial deficiency of the porphobilinogen deaminase, the enzyme of heme biosynthesis. The metabolic defect in AIP involves an approximately half-normal activity of porphobilinogen deaminase (PBGD, EC 4.3.1.8), the enzyme catalyzing condensation of four porphobilinogen molecules to hydroxymethylbilane. Due to tissue-specific alternative transcript splicing, the PBGD gene mutations within the range of exons 3–15 may lead to classical AIP involving erythrocytes and all the other tissues. Mutations within intron and exon 1 may result in the so-called non-erythroid AIP in which the PBGD activity is normal in erythrocytes and diminished in other tissues.
Objectives. The aim of the present study was to characterise molecular errors in the PBGD gene in Polish patients with non-erythroid AIP and to evaluate the efficacy of the DNA sequencing method in the early diagnosis of this disorder.
Material and Methods. Twenty five members of nine non-erythroid AIP families were assessed. In each of them DNA sequencing was performed using the Big Dye Terminator Cycle Sequencing Kit v.1.1 on the Hitachi 3730 Analyzer (Applied Biosystem, USA).
Results. Four mutations were detected in intron 1 of the PBGD gene, including one unreported novel mutation, 33+(4–12) del AGTGCTGAG, of an unknown biological mechanism, and three previously described mutations, i.e. 33+1 G > A, 33+2 T > C, 33+5 G > C, responsible for abnormal transcript splicing in the area of exon 1. Of 14 asymptomatic members of proband families in 6 subjects were diagnosed with AIP, and in 8 the AIP was excluded based on the DNA sequencing method.
Conclusion. DNA sequencing based analysis is the only reliable method for correct diagnosis of asymptomatic non-erythroid AIP patients with normal urinary excretion of heme precursors. The mutations found in Polish patients with non-erythroid AIP represented those of splice defect and resulted in abnormal exon 1 splicing.

Key words

non-erythroid AIP, mutations, PBGD.

References (21)

  1. Stölzel U, Stauch T, Doss MO: Porphyrias Internist (Berl) 2010, 51, 1525–1533.
  2. Badminton MN, Elder GH: Molecular mechanisms of dominant expression in porphyria. J Inherit Metab Dis 2005, 28, 277–286.
  3. Balwani M, Desnick RJ: The porphyrias: advances in diagnosis and treatment. Hematology 2012 American Society of Hematology Education Program 54th ASH Meeting Atlanta 2012, 19–27.
  4. Anderson KE, Sassa S, Bishop DF: Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In: Scriver CS, Beaudet AI, Sly WS et al, eds. The molecular and metabolic bases of inherited disease. 8th ed. New York: McGraw-Hill, 2001, 2961–3062.
  5. Kauppinen R, von and zu Fraunberg M: Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families. Clin Chem 2002, 48, 1891–1900.
  6. Miyagi K, Cardinal R, Bossenmaier I, Watson CJ: The serum porphobilinogen and hepatic porphobilinogen deaminase in normal and porphyric individuals. J Lab Clin Med 1971, 78, 683–695.
  7. Sassa S, Zalar GL, Kappas A: Studies in porphyria. VII. Induction of uroporphyrinogen –I synthase and expression of the gene defect of acute intermittent porphyria in mitogen-stimulated human lymphocytes. J Clin Invest 1978, 61, 499–508.
  8. Brancaleoni V, Granata F, Colancecco A, Tavazzi D, Cappellini HD, Di Pierro E: Seven novel genetic mutations within the 5’UTR and the housekeeping promoter of HMBS gene responsible for the non-erythroid form of acute intermittent porphyria. Blood Cells Mol Dis 2012, 49, 147–151.
  9. Sassa S, Kappas A: Molecular aspects of the inherited porphyrias. J Intern Med 2000, 247, 169–178.
  10. Namba H, Narahara K,Tsuji K, Yokoyama Y, Seino Y: Assignment of human porphobilinogen deaminase to 11q24.1–q24.2 by in situ hybridization and gene dosage studies. Cytogenet Cell Genet 1991, 57, 105–108.
  11. Yoo HW, Warner CA, Chen CH, Desnick RJ: Hydroxymethylbilane synthase: complete genomic sequence and amplifiable polymorphisms in the human gene. Genomics 1993, 15, 21–29.
  12. Innala E, Bāckström T, Bixo M, Andersson C: Evaluation of gonadotropin-releasing hormone agonist treatment for prevention of menstrual-related attacks in acute porphyria. Acta Obstet Gynecol Scand 2010, 89, 95–100.
  13. Anyaegbu EI, Goodman M, Ahn SY, Thangarajh M, Wong M, Shinawi M: Acute intermittent porphyria: a diagnostic challenge. J Child Neurol 2012, 27, 917–921.
  14. Bylesjö I, Wikberg A, Andersson C: Clinical aspects of acute intermittent porphyria in northern Sweden: a population-based study: Scand J Clin Lab Invest 2009, 69, 612–618.
  15. Mauzerall D, Granick S: The occurrence and determination of delta-aminolevulinic acid and porphobilinogen in urine. J Biol Chem 1956, 219, 435–446.
  16. Magnussen CR, Levine JB, Doherty JM, Cheesman JO, Tschudy DP: A red cell enzyme method for the diagnosis of acute intermittent porphyria. Blood 1974, 44, 875–868.
  17. Puy H, Deybach JC, Lamoril J, Robreau AM, Da Silva V, Gouya L, Grandchamp B, Nordmann Y: Molecular epidemiology and diagnosis of PBG deaminase gene defects in acute intermittent porphyria. Am J Hum Genet 1997, 60, 1373–1383.
  18. Hrdinka M, Puy H, Martasek P: May 2006 update in porphobilinogen deaminase gen polymorphisms and mutations causing acute intermittent porphyria: comparison with the situation in Slavic population. Physiol Res 2006, 55 (Suppl 2), 119–136.
  19. Szlendak U: Mutations of porphobilinogen deaminase gene (PBGD) in Polish Families with acute intermittent Porphyria (AIP). Doctoral Thesis, Institute of Haematology and Transfusion Medicine, Warsaw, 2009.
  20. Puy H, Gross U, Deybach JC, Robreau AM, Frank M, Nordmann Y, Doss M: Exon 1 donor splice site mutations in the porphobilinogen deaminase gene in the non-erythroid variant form of acute intermittent porphyria. Hum Genet 1998, 103, 570–575.
  21. Whatley SD, Roberts AG, Llewellyn DH, Bennett CP, Garrett C, Elder GH: Non-erythroid form of acute intermittent porphyria caused by promoter and frameshift mutations distant from the coding sequence of exon 1 of the HMBS gene. Hum Genet 2000, 107, 234–248.